Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys

Journal of Medicinal Chemistry

Volumn 46, Issue 12, 2003, Pages 2502-2515

  Boros, Eric E ^a   Samano, Vicente ^a   Ray, John A ^a   Thompson, James B ^a   Jung, David K ^a   Kaldor, Istvan ^a   Koble, Cecilia S ^a   Martin, Michael T ^a   Styles, Virgil L ^a   Mook Jr , Robert A ^a   Feldman, Paul L ^a   Savarese, John J ^b   Belmont, Matthew R ^b   Bigham, Eric C ^a   Boswell, G Evan ^c   Hashim, Mir A ^a   Patel, Sanjay S ^d   Wisowaty, James C ^a   Bowers, Gary D ^a   Moseley, Caroline L ^a   Walsh, John S ^a   Reese, Mindy J ^a   Rutkowske, Randy D ^a   Sefler, Andrea M ^a   Spitzer, Timothy D ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c PFIZER INC   (United States)

^d Avera Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 BENZYLTETRAHYDROISOQUINOLINIUM; 1,2 PHENYLTETRAHYDROISOQUINOLINIUM; BISONIUM CHLOROFUMARATE; CHLORINE; CURARE; DIMETHYLTUBOCURARINE CHLORIDE; DOXACURIUM; FUMARIC ACID DERIVATIVE; ISOQUINOLINE DERIVATIVE; MIVACURIUM; NEUROMUSCULAR BLOCKING AGENT; NEUROMUSCULAR DEPOLARIZING AGENT; SUXAMETHONIUM; TETRAHYDROISOQUINOLINIUM HALOFUMARATE DERIVATIVE; TETRAHYDROISOQUINOLINIUM HALOSUCCINATE DERIVATIVE; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANESTHETIC RECOVERY; ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; EVALUATION; FASCICULATION; HEART ARRHYTHMIA; HUMAN; HYPERKALEMIA; INTRAOCULAR HYPERTENSION; MALE; MALIGNANT HYPERTHERMIA; MYALGIA; NONHUMAN; RHESUS MONKEY; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANISOLES; BLOOD PRESSURE; FUMARATES; HEART RATE; HUMANS; ISOQUINOLINES; MACACA MULATTA; MALE; MUSCLE CONTRACTION; MUSCLE, SKELETAL; NEUROMUSCULAR BLOCKING AGENTS; QUATERNARY AMMONIUM COMPOUNDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SUCCINATES;

EID: 12444344895     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020574+     Document Type: Article

References (55)

1. Savarese, J. J.; Miller, R. D.; Lien, C. A.; Caldwell, J. E. Pharmacology of Muscle Relaxants and Their Antagonists. In Anesthesia, 4th ed.; Miller, R. D., Ed.; Churchill Livingstone: New York, 1994; pp 417-488.
2. (a) Lee, C. Structure, Conformation and Action of Neuromuscular Blocking Drugs. Br. J. Anaesth. 2001, 87, 755-769.
3. (b) Rees, D. C.; Hill, D. R. Drugs in Anesthetic Practice. Annu. Rep. Med. Chem. 1996, 31, 41-50.
4. (c) Bevan, D. R. Newer Neuromuscular Blocking Agents. Pharmacol. Toxicol. 1994, 74, 3-9.
5. 95 dose are defined by the FDA as ultrashort (8 min), short (20 min), intermediate (50 min), and long acting (≫50 min), see: Bedford, R. F. From the FDA. Anesthesiology 1995, 82, 33A.
6. (a) Naguib, M.; Flood, P.; McArdle, J. J.; Brenner, H. R. Advances in Neurobiology of the Neuromuscular Junction. Implications for the Anesthesiologist. Anesthesiology 2002, 96, 202-231.
7. (b) Mahajan, R. P. Is Suxamethonium Now Obsolete? Curr. Anaesth. Crit. Care 1996, 7, 289-294.
8. (c) Belmont, M. R. Succinylcholine/Suxamethonium. Curr. Opin. Anesthesiol. 1995, 8, 362-366.
9. (d) Durant, N. N.; Katz, R. L. Suxamethonium. Br. J. Anaesth. 1982, 54, 195-208.
10. (a) Sparr, H. J.; Beaufort, T. M.; Fuchs-Buder, T. Newer Neuromuscular Blocking Agents. How Do They Compare with Established Agents? Drugs 2001, 61, 919-942.
11. (b) White, P. F. Rapacuronium: Why Did It Fail as a Replacement for Succinylcholine? Br. J. Anaesth. 2002, 88, 163-165.
12. (c) Adam, J. M.; Bennett, D. J.; Bom, A.; Clark, J. K.; Feilden, H.; Hutchinson, E. J.; Palin, R.; Prosser, A.; Rees, D. C.; Rosair, G. M.; Stevenson, D.; Tarver, G. J.; Zhang, M.-Q. Cyclodextrin-Derived Host Molecules as Reversal Agents for the Neuromuscular Blocker Rocuronium Bromide: Synthesis and Structure-Activity Relationships. J. Med. Chem. 2002, 45, 1806-1816.
13. (d) Bom, A.; Bradley, M.; Cameron, K.; Clark, J. K.; Van Egmond, J.; Feilden, H.; MacLean, E. J.; Muir, A. W.; Palin, R.; Rees, D. C.; Zhang, M.-Q. A Novel Concept of Reversing Neuromuscular Block: Chemical Encapsulation of Rocuronium Bromide by a Cyclodextrin-Based Synthetic Host. Angew. Chem., Int. Ed. 2002, 41, 265-270.
14. (a) Dewar, G. H.; Marshall, I. G.; Patel, S. S.; Waigh, R. D. Chemodegradable Neuromuscular Blocking Agents-I: Bis-3,4-Dihydroisoquinolinium Salts. Pharm. Sci. Commun. 1993, 4, 3-14.
15. (B) Stenlake, J. B.; Williams, W. D.; Dhar, N. C.; Marshall, I. G. Neuromuscular Blocking Agents: Stereochemical Studies on 1-Benzyltetrahydroisoquinolinium Salts. Eur. J. Med. Chem. 1974, 9, 233-238 and references therein.
16. (c) Stenlake, J. B.; Dhar, N. C.; Haddow, J.; McDonald, I. M.; Maehr, R. B.; Wastila, W. B. Neuromuscular Blocking Agents. Some Approaches to Short Acting Compounds. Eur. J. Med. Chem. 1992, 27, 463-477.
17. (d) Dhar, N. C.; Maehr, R. B.; Masterson, L. A.; Midgley, J. M.; Stenlake, J. B.; Wastila, W. B. Approaches to Short-Acting Neuromuscular Blocking Agents: Nonsymmetrical Bis-tetrahydroisoquinolinium Mono- and Diesters. J. Med. Chem. 1996, 39, 556-561.
18. (e) Gyermek, L.; Lee, C.; Nguyen, N. Pharmacology of G-1-64, a New Nondepolarizing Neuromuscular Blocking Agent with Rapid Onset and Short Duration of Action. Acta Anaesthesiol. Scand. 1999, 43, 651-657.
19. This rare but well-known problem has been observed in the clinical application of both mivacurium and succinylcholine (see ref 1).
20. For examples of the inactive metabolite (soft drug) approach in drug design, see: (a) Hwang, S.-K.; Juhasz, A.; Yoon, S.-H.; Bodor, N. Soft Drugs. 12. Design, Synthesis, and Evaluation of Soft Bufuralol Analogues. J. Med. Chem. 2000, 43, 1525-1532.
21. (b) Feldman, P. L.; James, M. K.; Brackeen, M. F.; Bilotta, J. M.; Schuster, S. V.; Lahey, A. P.; Lutz, M. W.; Johnson, M. R.; Leighton, H. J. Design, Synthesis, and Pharmacological Evaluation of Ultra-Short- to Long-Acting Opioid Analgetics. J. Med. Chem. 1991, 34, 2202-2208 and references therein.
22. (a) Boros, E. E.; Bigham, E. C.; Mook, R. A., Jr.; Patel, S. S.; Savarese, J. J.; Ray, J. A.; Thompson, J. B.; Hashim, M. A.; Wisowaty, J. C.; Feldman, P. L.; Samano, V. Bis- and Mixed-Tetrahydroisoquinolinium Chlorofumarates: New Ultra-Short-Acting Nondepolarizing Neuromuscular Blockers. J. Med. Chem. 1999, 42, 206-209 and Supporting Information.
23. (b) Samano, V.; Ray, J. A.; Thompson, J. B.; Mook, R. A., Jr.; Jung, D. K.; Koble, C. S.; Martin, M. T.; Bigham, E. C.; Regitz, C. S.; Feldman, P. L.; Boros, E. E. Synthesis of Ultra-Short-Acting Neuromuscular Blocker GW 0430: A Remarkably Stereo- and Regioselective Synthesis of Mixed-Tetrahydroisoquinolinium Chlorofumarates. Org. Lett. 1999, 1, 1993-1996 and Supporting Information.
24. (a) Belmont, M. R.; Lien C. A.; Savarese, J. J.; Patel, S.; Fischer, G.; Mook, R. Neuromuscular Blocking Effects of GW280430A at the Adductor Pollicis and Larynx in Human Volunteers. Br. J. Anaesth. 1999, 82, A419.
25. (b) Moore, E. W.; Hunter, J. M. The New Neuromuscular Blocking Agents: Do They Offer Any Advantages? Br. J. Anaesth. 2001, 87, 912-925 and references therein.
26. Whaley, K. W.; Govindachari, T. R. The Preparation of 3,4-Dihydroisoquinolines and Related Compounds by the Bischler-Napieralski Reaction. Org. React. 1951, 6, 74-150.
27. Kaluszyner, A.; Galun, A. B. N-Methylation of Amino Alcohols and Amino Mercaptans. J. Org. Chem. 1961, 26, 3536-3537.
28. Swaringen, R. A., Jr.; El-Sayad, H. A.; Yeowell, D. A.; Savarese, J. J. Novel Compounds. US Patent 4,761,418, 1988.
29. Uematsu, N.; Fujii, A.; Hashiguchi, S.; Ikariya, T.; Noyori, R. Asymmetric Transfer Hydrogenation of Imines. J. Am. Chem. Soc. 1996, 118, 4916-4917.
30. Brossi, A.; Teitel, S. Synthesis and Absolute Configuration of Cryptostylines I, II, and III. Helv. Chim. Acta 1971, 54, 1564-1571.
31. Suzuki, H.; Aoyagi, S.; Kibayashi, C. Asymmetric Synthesis of 1-Substituted Tetrahydroisoquinolines by Nucleophilic Addition to Hydrazonium Ions. Application to the Enantioselective Syntheses of (+)- and (-)-Salsolidines and (-)-Cryptostyline II. Tetrahedron Lett. 1995, 36, 6709-6712.
32. (a) Bernath, G.; Kobor, J.; Koczka, K.; Radics, L.; Kajtar, M. Quaternization of 1,2-Disubstituted 6,7-Dimethoxy-1,2,3,4-Tetrahydroisoquinolines. Tetrahedron Lett. 1968, 225-229.
33. Ribar, B.; Lazar, D.; Kalman, A.; Kobor, J.; Bernath, G. Stereochemical Studies. Part 29. Crystal Structure of 2-Benzyl-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-phenylisoquinolinium Iodide. J. Chem. Soc., Perkin Trans. 2 1977, 1141-1144.
34. ElSayad, H. A.; Swaringen, R. A.; Yeowell, D. A.; Crouch, R. C.; Hurlbert, S.; Miller, R. W.; McPhail, A. T. Nuclear Magnetic Resonance and X-ray Stereochemical Studies on 1-Benzyltetrahydroisoquinolinium Salts. J. Chem. Soc., Perkin Trans. 1 1982, 2067-2077.
35. Kaldor, I.; Feldman, P. L.; Mook, R. A., Jr.; Ray, J. A.; Samano, V.; Sefler, A. M.; Thompson, J. B.; Travis, B. R.; Boros, E. E. Stereocontrolled Synthesis of cis-Dibenzoquinolizine Chlorofumarates: Curare-Like Agents of Ultrashort Duration. J. Org. Chem. 2001, 66, 3495-3501.
36. Akhtar, M.; Botting, N. P.; Cohen, M. A.; Gani, D. Enantiospecific Synthesis of 3-Substituted Aspartic Acids via Enzymic Amination of Substituted Fumaric Acids. Tetrahedron 1987, 43, 5899-5908.
37. (a) Erickson, L. E. Proton Nuclear Magnetic Resonance Spectra of Substituted Succinic Anhydrides, Acids, Salts and Esters. J. Am. Chem. Soc. 1965, 87, 1867-1875.
38. Feuer, H.; Rubinstein, H. Preparation of 1-(3′,1′H,6′-Pyridazinone)-3,6-pyridazinedione. Attempts to Prepare Bicyclic Dimaleic Hydrazide. J. Org. Chem. 1959, 24, 811-813.
39. (a) Lowe, G.; Potter, B. V. L. Synthesis, Absolute Configuration, and Circular Dichroism of the Enantiomers of Fluorosuccinic Acid. J. Chem. Soc., Perkin Trans. 1 1980, 2029-2032.
40. (b) Leeper, F. J.; Rock, M. The Synthesis of a Fluorinated Analogue of 5-Aminolaevulinic Acid, A Potential Inhibitor of Porphyrin Biosynthesis. J. Fluorine Chem. 1991, 51, 381-396.
41. 3 and Intermediates Obtained Therefrom. US Patent 4,421,690, 1988.
42. (a) Tsukamoto, T.; Kitazume, T. Preparation and Reaction of Difluorinated Malonaldehydic Acid Derivatives: A New Route to Functionalized α,α-Difluorinated Esters and Amides. J. Chem. Soc., Perkin Trans. 1 1993, 1177-1181.
43. (b) Tsukamoto, T.; Kitazume, T. Difluorinated Malonaldehyde Derivatives as Useful Difluoromethylene-Containing Building Blocks. J. Chem. Soc., Chem. Commun. 1992, 540-541.
44. 2 Compounds. US Patent 4,324,730, 1982.
45. For similar examples of regio- and stereoselective elimination of HCl from 2,3-dichloropropanoates, see: Mercedes, C. C.; Garay, R. O. Elimination from Diastereomeric Methyl 3-Acetoxy-2-halogeno- and 2,3-Dihalogeno-3-phenylpropanoates. J. Chem. Soc., Perkin Trans. 2 1987, 1473-1476.
46. The intubating dose for succinylcholine in humans (1 mg/kg) produces ablation of the twitch response in 60-90 s and 95% recovery in 12-15 min after injection (see ref 1).
47. 95 in humans (0.15 mg/kg), mivacurium provides complete suppression of the twitch response in 2-4 min and 95% recovery in 20-30 min following injection (see ref 2c).
48. 95 (0.2 mg/kg): see (a) Frampton, J. E.; McTavish, D. Mivacurium: A Review of its Pharmacology and Therapeutic Potential in General Anaesthesia. Drugs 1993, 45, 1066-1089.
49. (b) Savarese. J. J. Mivacurium: A Comparison with Other Benzylisoquinolinium Nondepolarizing Muscle Relaxants. J. Drug Dev. 1993, 5, 1-5.
50. (a) Bowman, W. C.; Rodger, I. W.; Houston, J.; Marshall, R. J.; McIndewar, I. Structure: Action Relationships among Some Desacetoxy Analogues of Pancuronium and Vecuronium in the Anesthetized Cat. Anesthesiology 1988, 69, 57-62.
51. (b) Kopman, A. F. Onset of Action of Neuromuscular Blockade: Contributing Factors. Curr. Opin. Anaesth. 1992, 5, 561-567.
52. 1H NMR analysis.
53. Compound 24a has a half-life of ca. 178 days in pH 3 saline at 23 °C. Its half-life in pH 7.4 phosphate buffer at 37 °C is ca. 37 min.
54. (a) Reese, M. J.; Walsh, J. S.; Spitzer, T.; Bower, G.; Stafford, C. Comparative Metabolic Profiles of the Neuromuscular Blocker GW280430 in Human, Monkey, and Dog, and Characterization of a Major Metabolite as an Unusual Cyclized Cysteine Conjugate. Presented at the 9th North American ISSX Meeting (issx.org); Nashville, TN.; October, 1999.
55. (b) Spitzer, T.; Walsh, J.; Reese, M.; Stafford, C.; Facchine, K.; Burinsky, D.; Sides, S. Structure Elucidation of the Primary Metabolite of the Neuromuscular Blocker GW280430A. Presented at the SMASH NMR Conference (smashnmr.org); Argonne, IL.; July, 1999.